Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Accelerating sustainability in Indian pharma industry
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
